Radiopharmaceuticals and Radiochemicals
for research and clinical use
We are a leading provider of PET-radiopharmaceuticals and radionuclides for the nuclear medicine community. The nuclear medicine community in the Benelux region and beyond successfully uses our GMP-compliant radiopharmaceuticals and radionuclides in all stages of clinical care: from pre-clinical research to clinical studies and commercial usage.
Founded in 1987, BV Cyclotron VU rapidly developed into a well-established producer of radiopharmaceuticals and radionuclides for imaging techniques, such as PET and SPECT. Equipped with three cyclotrons and several clean room facilities, we are at the forefront of the nuclear medicine community, with location on the campus of the VU University Amsterdam.
We currently employ about 30 people. Our portfolio offers seven products, with a production output of 35,000 patient doses per year:
- Iodine-124 [124I ]
- Zirconium-89 [89Zr ]
- Fludeoxyglucose [18FFDG ]
- 81Rb/81mKr Generator
- Type A Transport Container
- Sodium Iodide [124I for Injection ]
*Other 18F-tracers: – Fluoromethycholine – Florbetaben – Sodium Fluoride [18F ]
News and articles that we find of particular interest:
2/8/2013: Last week, researchers at the VU University Medical Center (VUmc) in Amsterdam received a 1-million Euro funding for a multicenter trial in head and neck cancer patients. The funding, granted by KWF/Alpe d’HuZes, will be used by the VUmc to produce 89Zr-radiolabeled antibodies for leading oncological centers in Europe.
27/5/2013: Researchers from the Department of Medical Oncology at the University Medical Center Groningen (the Netherlands) carried out a clinical feasibility study in order to determine whether VEGF-A could be visualized by PET imaging with 89Zr-bevacizumab in patients with primary breast cancer, wich positive results.